Nuvation Bio Inc - Ordinary Shares - Class A

NYSE:NUVB   3:59:52 PM EDT
5.62
-0.39 (-6.49%)
4:00:00 PM EDT: $5.61 -0.01 (-0.18%)
Products

Nuvation Bio Announces FDA Clearance Of Clinical Trial Application For Nuv-422 For The Treatment Of Prostate Cancer

Published: 12/13/2021 12:28 GMT
Nuvation Bio Inc - Ordinary Shares - Class A (NUVB) - Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for Nuv-422 for the Treatment of Prostate Cancer.